ASPIRE Trial - KRd VS Rd - Multiple Myeloma Clinical Trials
Clinical Trials in R/R Multiple Myeloma
Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews - ScienceDirect
Dr. Reddy's Laboratories Ltd. - Multiple myeloma is a cancer of plasma cells that generally affects people in the age group of 52-61 years and early diagnosis is possible with routine blood
Emerging immunotherapies in multiple myeloma | The BMJ
The Changing Face of Multiple Myeloma | GoToPER.com
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
Cancers | Free Full-Text | Genome Instability in Multiple Myeloma: Facts and Factors
Healthcare reality of the treatment of the high-risk multiple myeloma in Spain | Medicina Clínica (English Edition)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Carfilzomib in multiple myeloma | PPT
Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost | International Journal of Hematology
Frontiers | Therapeutic strategies to enhance immune response induced by multiple myeloma cells
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
Biomedicines | Free Full-Text | Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Cardiovascular Complications of Novel Multiple Myeloma Treatments | Circulation
How I treat high-risk multiple myeloma - ScienceDirect
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Carfilzomib in multiple myeloma | PPT
Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena
Multiple myeloma | Nature Reviews Disease Primers
